Modality
Peptide
MOA
SGLT2i
Target
FcRn
Pathway
Epigenetic
CTCL
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
~Aug 2019
→ ~Nov 2020
Phase 3
Feb 2021
→ Apr 2025
Phase 3Current
NCT04489412
681 pts·CTCL
2021-08→2025-04·Completed
NCT08057825
762 pts·CTCL
2021-02→TBD·Not yet recruiting
1,443 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-04-0112mo agoPh3 Readout· CTCL
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
P3
Not yet…
P3
Complet…
Catalysts
Ph3 Readout
2025-04-01 · 12mo ago
CTCL
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04489412 | Phase 3 | CTCL | Completed | 681 | EDSS |
| NCT08057825 | Phase 3 | CTCL | Not yet recr... | 762 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 |